

Hyperthermia intensifies gambogic acid and synthetic xanthones' antimalignancy properties.

Jakub Rech^{1,*}, Dorota Żelaszczyk², Henryk Marona², Agnieszka Gunia-Krzyżak², Paweł Żmudzki³ and Ilona Bednarek¹

¹ Department of Biotechnology and Genetic Engineering, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland; jrech@sum.edu.pl (J.R), ibednarek@sum.edu.pl (I.B.)

² Department of Bioorganic Chemistry, Chair of Organic Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Krakow, Poland; dorota.zelaszczyk@uj.edu.pl (D.Z.); henryk.marona@uj.edu.pl (H.M.); agnieszka.gunia@uj.edu.pl (A.G-K)

³ Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, 30-688 Krakow, Poland; pawel.zmudzki@uj.edu.pl (P.Z.)

* Correspondence: jrech@sum.edu.pl

Intermediate products

Compound 1





Figure S1

Compound 2







Figure S2

Compound 4



170406_K-43-17A



170406_K-43-17A 1021 (9.201)




Figure S3

Compound 4





Figure S4

Final compounds

C1





Figure S5

C1





Figure S6

C1





Figure S7

C2






Figure S8

C2





Figure S9

C2





Figure S10

C3






Figure S11

C3





Figure S12

C3





Figure S13

C4






Figure S14

C4





Figure S15

C4





Figure S16

C5






Figure S17

C5





Figure S18

C5





Figure S19

C6






Figure S20

C6





Figure S21

C6





Figure S22

C7




Figure S23

C7





Figure S24

C7







Figure S25

C8



180305_H-35-18A



180305_H-35-18A 345 (3.441)




Figure S26

C8





Figure S27

C8





Figure S28

Table S1

L929	IC50 [µM]	IC25 [µM]	GI10 [µM]
CIS	121,71	78,45	52,50
MAG	32,48	15,26	4,92
C8	59,64	32,50	16,21
C7	27,57	16,61	10,04

Table S1. L929 growth inhibition (GI) values in 37°C for 24h